251 related articles for article (PubMed ID: 18471161)
1. Caspofungin for treatment of invasive aspergillus infections.
Heinz WJ; Einsele H
Mycoses; 2008; 51 Suppl 1():47-57. PubMed ID: 18471161
[TBL] [Abstract][Full Text] [Related]
2. Caspofungin as first-line therapy for the treatment of invasive aspergillosis after thoracic organ transplantation.
Groetzner J; Kaczmarek I; Wittwer T; Strauch J; Meiser B; Wahlers T; Daebritz S; Reichart B
J Heart Lung Transplant; 2008 Jan; 27(1):1-6. PubMed ID: 18187079
[TBL] [Abstract][Full Text] [Related]
3. Clinical evidence for caspofungin monotherapy in the first-line and salvage therapy of invasive Aspergillus infections.
Heinz WJ; Buchheidt D; Ullmann AJ
Mycoses; 2016 Aug; 59(8):480-93. PubMed ID: 27324802
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes of lung-transplant recipients treated by voriconazole and caspofungin combination in aspergillosis.
Thomas A; Korb V; Guillemain R; Caruba T; Boussaud V; Billaud E; Prognon P; Begué D; Sabatier B
J Clin Pharm Ther; 2010 Feb; 35(1):49-53. PubMed ID: 20175811
[TBL] [Abstract][Full Text] [Related]
5. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study.
Singh N; Limaye AP; Forrest G; Safdar N; Muñoz P; Pursell K; Houston S; Rosso F; Montoya JG; Patton P; Del Busto R; Aguado JM; Fisher RA; Klintmalm GB; Miller R; Wagener MM; Lewis RE; Kontoyiannis DP; Husain S
Transplantation; 2006 Feb; 81(3):320-6. PubMed ID: 16477215
[TBL] [Abstract][Full Text] [Related]
6. Caspofungin therapy in immunocompromised children and neonates.
Somer A; Törün SH; Salman N
Expert Rev Anti Infect Ther; 2011 Mar; 9(3):347-55. PubMed ID: 21417874
[TBL] [Abstract][Full Text] [Related]
7. Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin.
Raad II; Hanna HA; Boktour M; Jiang Y; Torres HA; Afif C; Kontoyiannis DP; Hachem RY
Leukemia; 2008 Mar; 22(3):496-503. PubMed ID: 18094720
[TBL] [Abstract][Full Text] [Related]
8. [Guideline based treatment of invasive aspergillosis].
Karthaus M
Mycoses; 2010 May; 53 Suppl 1():36-43. PubMed ID: 20433655
[TBL] [Abstract][Full Text] [Related]
9. Caspofungin plus posaconazole as salvage therapy of invasive fungal infections in immunocompromised patients.
Lellek H; Waldenmaier D; Dahlke J; Ayuk FA; Wolschke C; Kröger N; Zander AR
Mycoses; 2011 Jan; 54 Suppl 1():39-44. PubMed ID: 21126271
[TBL] [Abstract][Full Text] [Related]
10. Amphotericin B-resistant Aspergillus flavus infection successfully treated with caspofungin, a novel antifungal agent.
Koss T; Bagheri B; Zeana C; Romagnoli MF; Grossman ME
J Am Acad Dermatol; 2002 Jun; 46(6):945-7. PubMed ID: 12063497
[TBL] [Abstract][Full Text] [Related]
11. Economic evaluation of targeted treatments of invasive aspergillosis in adult haematopoietic stem cell transplant recipients in the Netherlands: a modelling approach.
Ament AJ; Hübben MW; Verweij PE; de Groot R; Warris A; Donnelly JP; van 't Wout J; Severens JL
J Antimicrob Chemother; 2007 Aug; 60(2):385-93. PubMed ID: 17561501
[TBL] [Abstract][Full Text] [Related]
12. Breakthrough invasive aspergillosis in allogeneic haematopoietic stem cell transplant recipients treated with caspofungin.
Madureira A; Bergeron A; Lacroix C; Robin M; Rocha V; de Latour RP; Ferry C; Devergie A; Lapalu J; Gluckmana E; Socié G; Ghannoum M; Ribaud P
Int J Antimicrob Agents; 2007 Dec; 30(6):551-4. PubMed ID: 18029149
[TBL] [Abstract][Full Text] [Related]
13. Clinical experience of the use of voriconazole, caspofungin or the combination in primary and salvage therapy of invasive aspergillosis in haematological malignancies.
Raad II; Zakhem AE; Helou GE; Jiang Y; Kontoyiannis DP; Hachem R
Int J Antimicrob Agents; 2015 Mar; 45(3):283-8. PubMed ID: 25455847
[TBL] [Abstract][Full Text] [Related]
14. Caspofungin: a major breakthrough in treatment of systemic fungal infections.
Agarwal MB; Rathi SA; Ratho N; Subramanian R
J Assoc Physicians India; 2006 Dec; 54():943-8. PubMed ID: 17334012
[TBL] [Abstract][Full Text] [Related]
15. The echinocandins: three useful choices or three too many?
Bal AM
Int J Antimicrob Agents; 2010 Jan; 35(1):13-8. PubMed ID: 19942413
[TBL] [Abstract][Full Text] [Related]
16. [symbol: see text]Caspofungin and [symbol: see text]voriconazole for fungal infections.
Drug Ther Bull; 2004 Jan; 42(1):5-8. PubMed ID: 14768298
[TBL] [Abstract][Full Text] [Related]
17. [Role of anidulafungin in solid organ transplant recipients].
Aguado JM; Ayats J
Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 14():29-34. PubMed ID: 19572432
[TBL] [Abstract][Full Text] [Related]
18. Prophylaxis and treatment of invasive aspergillosis with voriconazole, posaconazole and caspofungin: review of the literature.
Karthaus M
Eur J Med Res; 2011 Apr; 16(4):145-52. PubMed ID: 21486728
[TBL] [Abstract][Full Text] [Related]
19. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
20. Successful combined antifungal salvage therapy with liposomal amphothericin B and caspofungin for invasive Aspergillus flavus infection in a child following allogeneic bone marrow transplantation.
Kriván G; Sinkó J; Nagy IZ; Goda V; Reményi P; Bátai A; Lueff S; Kapás B; Réti M; Tremmel A; Masszi T
Acta Biomed; 2006; 77 Suppl 2():17-21. PubMed ID: 16918062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
